The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant.
作者信息
Beck-da-Silva Luís, Rohde Luís E
机构信息
Serviço de Cardiologia - Hospital de Clínicas de Porto Alegre, Porto Alegre, RS - Brazil.
Programa de Pós-Graduação em Cardiologia e Ciências Cardiovasculares - Faculdade de Medicina da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS - Brazil.
出版信息
Arq Bras Cardiol. 2019 Jul 15;112(6):791-792. doi: 10.5935/abc.20190080.
Abstract
摘要
相似文献
1
The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant.沙库巴曲缬沙坦的利尿作用可能具有临床相关性。
Arq Bras Cardiol. 2019 Jul 15;112(6):791-792. doi: 10.5935/abc.20190080.
2
[Update on the clinical application of valsartan/sacubitril in patients with heart failure].[缬沙坦/沙库巴曲在心力衰竭患者中的临床应用进展]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jun 24;45(6):538-541. doi: 10.3760/cma.j.issn.0253-3758.2017.06.018.
3
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.在PARADIGM-HF试验（ARNI与ACEI前瞻性比较以确定对心力衰竭全球死亡率和发病率的影响）中，根据背景治疗情况，沙库巴曲缬沙坦的疗效。
Circ Heart Fail. 2016 Sep;9(9). doi: 10.1161/CIRCHEARTFAILURE.116.003212.
4
[Sacubitril-valsartan is a new cornerstone in heart failure therapy].沙库巴曲缬沙坦是心力衰竭治疗的新基石。
Lakartidningen. 2016 Jul 13;113:D6UU.
5
Sacubitril/Valsartan in Clinical Practice: The Italian Experience.沙库巴曲缬沙坦在临床实践中的应用：意大利经验
Cardiology. 2017;138 Suppl 1:1-2. doi: 10.1159/000484865. Epub 2017 Dec 21.
6
Sacubitril-Valsartan for the Treatment of Heart Failure: Effectiveness and Value.沙库巴曲缬沙坦治疗心力衰竭：有效性与价值
JAMA Intern Med. 2016 Feb;176(2):249-50. doi: 10.1001/jamainternmed.2015.7661.
7
Sacubitril-valsartan: novel therapy for heart failure.沙库巴曲缬沙坦：心力衰竭的新型疗法。
Can Fam Physician. 2017 Sep;63(9):697.
8
Sacubitril/Valsartan (Entresto): The Next Blockbuster Medication?沙库巴曲缬沙坦（诺欣妥）：下一个重磅药物？
S D Med. 2015 Nov;68(11):510-1.
9
Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.沙库巴曲缬沙坦的长期治疗获益评估
N Engl J Med. 2015 Dec 3;373(23):2289-90. doi: 10.1056/NEJMc1509753.
10
[Sacubitril/valsartan receives European approval].沙库巴曲缬沙坦获欧洲批准
MMW Fortschr Med. 2015 Dec 14;157(21-22):84. doi: 10.1007/s15006-015-7627-5.
本文引用的文献
1
Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide.沙库巴曲缬沙坦对单次呋塞米药代动力学和药效学的影响。
Br J Clin Pharmacol. 2018 May;84(5):926-936. doi: 10.1111/bcp.13505. Epub 2018 Feb 20.
2
Rational and design of a randomized, double-blind, multicenter trial to evaluate the safety and tolerability of furosemide withdrawal in stable chronic outpatients with heart failure: The ReBIC-1 trial.一项评估稳定型慢性心力衰竭门诊患者停用呋塞米安全性和耐受性的随机、双盲、多中心试验的原理与设计：ReBIC-1试验
Am Heart J. 2017 Dec;194:125-131. doi: 10.1016/j.ahj.2017.08.012. Epub 2017 Aug 24.
3
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
4
Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis.采用倾向评分匹配分析评估利尿剂剂量对急性心力衰竭患者死亡率的影响。
Eur J Heart Fail. 2011 Nov;13(11):1244-52. doi: 10.1093/eurjhf/hfr121.
5
Diuretic strategies in patients with acute decompensated heart failure.急性失代偿性心力衰竭患者的利尿剂策略。
N Engl J Med. 2011 Mar 3;364(9):797-805. doi: 10.1056/NEJMoa1005419.
6
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.血管紧张素受体阻滞剂缬沙坦用于慢性心力衰竭的一项随机试验。
N Engl J Med. 2001 Dec 6;345(23):1667-75. doi: 10.1056/NEJMoa010713.
Zotero 插件